Therapeutic Vaccines for Glioblastoma and Other Brain Tumors
Last updated 4/27/25
Concept
Cancer vaccines train a patient's immune system to recognize tumor-specific antigens and mount a durable T-cell response that helps keep residual cancer in check. Unlike preventive vaccines, these therapeutic vaccines are given after diagnosis, usually alongside surgery, radiation and temozolomide.
Vaccine Classes
- Tumor-lysate dendritic-cell vaccines - Autologous dendritic cells pulsed with the patient's own tumor lysate to present a broad repertoire of neoantigens (e.g., DCVax-L).
- Peptide vaccines - Short synthetic peptides representing one or more tumor antigens mixed with an adjuvant (e.g., SurVaxM, ITI-1001).
- mRNA vaccines - Lipid-nanoparticle mRNA encoding patient-specific neoantigens; early-phase GBM studies are recruiting (e.g., BNT-201 by BioNTech).
Representative Candidates
| Product | Platform | Target Antigen(s) | Clinical Status |
|---|---|---|---|
| DCVax-L (Northwest Bio) | Tumor-lysate dendritic cells | Patient-specific neoantigens | Phase 3 complete; marketing application under review by UK MHRA (2024) |
| SurVaxM (MimiVax) | Peptide + Montanide + sargramostim | Survivin (MHC I & II) | Phase 2b randomized trial enrolling (SURVAXM-001) |
| NeoVax / ITI-1001 (Dana-Farber / Immunomic) | Personalized peptide pool + Poly-ICLC | Top 20 neoantigens per patient | Phase 1 complete; combination trials planned |
| Gliovac (ERC-1671) | Allogeneic + autologous tumor-lysate mix with GM-CSF + cyclophosphamide | Heterogeneous whole-tumor antigens | Phase 2 data; available in the US under Right-to-Try or single-patient IND |
How They Are Used
- Treatment window: Most protocols start 3-8 weeks after chemoradiation, once steroids are ≤2 mg/day dexamethasone.
- Companion therapy: Vaccines are frequently paired with low-dose temozolomide, Poly-ICLC or checkpoint inhibitors to boost immunogenicity.
- Dosing schedule: Typically injected every 2-4 weeks for 3-6 doses, followed by maintenance boosters every 2-3 months.
Key Research Highlights
- DCVax-L phase 3 (2023) - Median OS 19.3 mo in newly diagnosed GBM vs 16.5 mo in matched controls; 4-yr OS 15%.
- SurVaxM phase 2 (2022) - 96% six-month PFS; 51% two-year OS with TMZ.
- NeoVax pilot (2021) - Robust neoantigen-specific T-cell immunity; 4 of 8 patients disease-free >3 yrs.
- Gliovac phase 2 (2021) - Median OS 12 mo in recurrent GBM; 24% two-year OS.
Access and Availability
- DCVax-L: Not commercially available. A Special Access Programme is open in the UK; contact Northwest Bio for details. No US expanded-access sites at present.
- SurVaxM: Accessible only through the SURVAXM-001 multicenter trial in the US.
- Gliovac: Available under the US Right-to-Try Act or single-patient IND; contact ERC Belgium or partner sites.
- Personalized peptide or mRNA vaccines: Limited to early-phase trials at Dana-Farber, Penn, BioNTech, etc.
Frequently Asked Questions
Can I start a vaccine if I'm still on steroids?
High-dose steroids (>2 mg/day dex) blunt T-cell priming. Most studies require taper to ≤2 mg/day before the first dose.
How soon will it work?
Immune monitoring shows peak neoantigen-specific T cells by roughly week 12; radiographic responses usually lag 3-6 months.
What about cost?
Investigational vaccines are free in trials. Commercial pricing will be set after regulatory approval and insurer negotiations.